OncoVAX: Global Drug Analysis (2016-2017) with Forecasts to 2025 - ResearchAndMarkets.com

DUBLIN--()--The "Drug analysis: OncoVAX" drug pipelines has been added to ResearchAndMarkets.com's offering.

OncoVAX (Vaccinogen) is a personalized cancer vaccine that uses the patient's own cancer cells to prevent tumor progression after surgery.

Vaccinogen uses a proprietary method for dissociating and purifying cancer cells from a resected tumor, and the resulting vaccine is thought to induce a robust and functional immune response in the patient. To prepare the vaccine, autologous tumors are excised, enzymatically dissociated to separate tumor cells from healthy cells, and irradiated to render the tumor cells non-proliferating and non-tumorigenic, but metabolically active. Patients receive four intradermal immunizations over the span of six months, as per the OncoVAX protocol: two injections consisting of irradiated tumor cells compounded with a live-attenuated mycobacteria adjuvant, followed by two injections consisting of irradiated cells only.

Following promising results from a Phase IIIa trial, a confirmatory Phase IIIb trial in Stage II resected colon cancer was initiated in May 2015.

Key Topics Covered:

Product Profiles

OncoVAX: Colorectal cancer (CRC)

List of Figures

Figure 1: OncoVAX for colon cancer - SWOT analysis

Figure 2: Drug assessment summary of OncoVAX for colon cancer

Figure 3: Drug assessment summary of OncoVAX for colon cancer

Figure 4: OncoVAX sales for colon cancer in the US, 2016-25

List of Tables

Table 1: OncoVAX drug profile

Table 2: OncoVAX Phase III trial in colon cancer

Table 3: OncoVAX Phase III data in colon cancer

Table 4: OncoVAX sales for colon cancer in the US ($m), 2016-25

Table 5: Patients treated with OncoVAX in the US, 2016-25

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/9ptgcg/oncovax_global?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cancer Vaccines

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Cancer Vaccines